An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.